{"id":"https://openalex.org/W4362527744","doi":"https://doi.org/10.1158/1535-7163.22508679","title":"Supplementary Table 3 from Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance","display_name":"Supplementary Table 3 from Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance","publication_year":2023,"publication_date":"2023-04-03","ids":{"openalex":"https://openalex.org/W4362527744","doi":"https://doi.org/10.1158/1535-7163.22508679"},"language":"en","primary_location":{"id":"doi:10.1158/1535-7163.22508679","doi":"https://doi.org/10.1158/1535-7163.22508679","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22508679","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1158/1535-7163.22508679","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5087945312","display_name":"Kristina Bennet Emdal","orcid":"https://orcid.org/0000-0002-9789-0665","observed_orcids":["https://orcid.org/0000-0002-9789-0665"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kristina B. Emdal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033039222","display_name":"Antje Dittmann","orcid":"https://orcid.org/0000-0002-2570-5192","observed_orcids":["https://orcid.org/0000-0002-2570-5192"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antje Dittmann","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086810628","display_name":"Raven J. Reddy","orcid":"https://orcid.org/0000-0002-3856-7454","observed_orcids":["https://orcid.org/0000-0002-3856-7454"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Raven J. Reddy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017738788","display_name":"Rebecca S. Lescarbeau","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rebecca S. Lescarbeau","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114144119","display_name":"Sheri L. Moores","orcid":"https://orcid.org/0000-0001-8888-192X","observed_orcids":["https://orcid.org/0000-0001-8888-192X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sheri L. Moores","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043253847","display_name":"Sylvie G. Laquerre","orcid":"https://orcid.org/0009-0006-8742-0201","observed_orcids":["https://orcid.org/0009-0006-8742-0201"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Sylvie Laquerre","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5002079869","display_name":"Forest M. White","orcid":"https://orcid.org/0000-0002-1545-1651","observed_orcids":["https://orcid.org/0000-0002-1545-1651"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Forest M. White","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9945999979972839,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10755","display_name":"HER2/EGFR in Cancer Research","score":0.003800000064074993,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/osimertinib","display_name":"osimertinib","score":0.9760000109672546},{"id":"https://openalex.org/keywords/egfr-met-bispecific-antibody","display_name":"EGFR-MET bispecific antibody","score":0.9789999723434448},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.8050000071525574},{"id":"https://openalex.org/keywords/egfr","display_name":"EGFR","score":0.492000013589859},{"id":"https://openalex.org/keywords/met","display_name":"MET","score":0.8180000185966492},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.8339999914169312}],"concepts":[{"id":"https://openalex.org/C2777626846","wikidata":"https://www.wikidata.org/wiki/Q21506464","display_name":"Osimertinib","level":5,"score":0.8616641759872437},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.44109925627708435},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.36889755725860596},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.28942880034446716},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2294396162033081},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.14212605357170105},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.12777510285377502},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.09758219122886658},{"id":"https://openalex.org/C2778087573","wikidata":"https://www.wikidata.org/wiki/Q418369","display_name":"Erlotinib","level":4,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1535-7163.22508679","doi":"https://doi.org/10.1158/1535-7163.22508679","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22508679","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.1158/1535-7163.22508679","doi":"https://doi.org/10.1158/1535-7163.22508679","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1535-7163.22508679","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.8048999905586243}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2747268799","https://openalex.org/W4392688639","https://openalex.org/W6921021352","https://openalex.org/W4294941732","https://openalex.org/W2767785738","https://openalex.org/W4362491809","https://openalex.org/W4223483831","https://openalex.org/W4388045355","https://openalex.org/W2809980410","https://openalex.org/W3138307077"],"abstract_inverted_index":{"Summary":[0],"of":[1],"data":[2],"from":[3],"drug":[4],"resistance":[5],"evaluation":[6]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2023-04-06T00:00:00"}